The Icahn School of Medicine based in New York has released its first blockchain-intended research center.
New employees undertake to investigate how the advanced technology can influence the healthcare system as well as design their own solutions-based models. New prototypes will aim to improve the drug development system and protect customers against counterfeit products.
The Icahn School of Medicine is managed by Joel Dudley, Executive VP of Precision Health at Mount Sinai. He has previously been a senior data scientist at Pivotal Software, aiming at exploring the artificial intelligence within biology.
“This experience will allow us to address many of the most promising uses for blockchain in biomedicine with the goal of improving healthcare delivery and reducing costs,” Dudley stated in a statement. “Many companies are already exploring the use of blockchain technologies in biology and healthcare,” reported Healthcare IT News.
“Our aim is to understand how blockchain and associated technologies can be applied to unmet needs in healthcare and biomedicine,” Dudley added.
Joel Dudley will have the role of creating divining health prototypes apps that will rely on data from electronic evidence and other digital sources.
Among the first projects, the center has developed a database of 114 businesses that deal with blockchain-based solutions dedicated to health care uses. As reported by Crain’s New York, the companies collected $ 670 million following an Initial Coin Offering (ICO). Two of the companies are CoverUs – a company that helps patients receive funding for their health data by using a specific tech, and Embleema – aiming to correlate patient information with electronically stored data.